ACAD
ACADIA Pharmaceuticals Inc
20.00$
+0.3%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +18.4% | +14.2% | +6.9% | +6.9% | +21.6% | -4.7% | +8.2% | +8.6% | +17.5% | +2.6% | +8.6% | |
| – | +23.4% | +9.6% | +7.9% | +8.1% | +19.0% | -7.2% | +10.3% | +12.1% | -1.3% | +3.2% | +11.7% | |
| – | +92.1% | +8.5% | -13.5% | -12.4% | +106.0% | -31.9% | +16.5% | +1.7% | -31.1% | +58.8% | +36.4% | |
| – | +26.9% | +7.2% | +6.5% | +12.9% | +33.7% | -9.8% | +11.8% | +11.2% | -3.2% | +3.9% | +12.3% | |
| – | +8.3% | -2.2% | +10.3% | -11.0% | +6.6% | +8.6% | +5.3% | +16.5% | +6.3% | +0.1% | +12.1% | |
| – | +72.5% | +72.9% | +15.5% | -14.7% | -64.0% | +4.6% | +13.8% | +11.4% | +19.2% | -8.9% | +2.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -2.0% | +68.3% | -2.1% | -2.2% | +13.5% | -2.3% | -2.3% | -2.4% | -2.4% | -2.5% | -2.6% | |
| – | +17.3% | +23.3% | +1.6% | +0.6% | +13.8% | -19.3% | +9.8% | +2.6% | -18.5% | +6.0% | +22.2% | |
| – | +21.3% | +30.0% | +2.2% | +1.8% | +14.8% | -23.4% | +9.1% | +8.0% | -22.3% | +10.3% | +18.3% | |
| – | +4.1% | +11.1% | +0.2% | -14.5% | +11.3% | +14.2% | +2.8% | +0.8% | -1.3% | +1.4% | +21.3% | |
| – | +42.5% | +10.2% | +2.8% | -4.0% | -15.1% | +11.8% | +11.1% | +8.2% | -49.9% | +12.3% | +263.9% | |
| – | +19.2% | +7.5% | +11.3% | +11.7% | +27.0% | +4.4% | +7.5% | +11.5% | +33.8% | +1.7% | +4.7% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +1.4% | +0.1% | -0.3% | +0.0% | +0.1% | +0.8% | +0.6% | +1.2% | +0.4% | +0.8% | +0.1% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.